(HLN) Haleon - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 44.640m USD | Total Return: 9% in 12m

Oral Care, Vitamins, Pain Relief, Cold Relief, Digestive Health
Total Rating 57
Safety 90
Buy Signal -0.13
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3
Market Cap: 44.6B
Avg Turnover: 88.0M USD
ATR: 2.10%
Peers RS (IBD): 20.8
Risk 5d forecast
Volatility19.9%
Rel. Tail Risk-1.03%
Reward TTM
Sharpe Ratio-0.08
Alpha-2.94
Character TTM
Beta-0.141
Beta Downside-0.178
Drawdowns 3y
Max DD23.11%
CAGR/Max DD0.21
EPS (Earnings per Share) EPS (Earnings per Share) of HLN over the last years for every Quarter: "2021-03": null, "2021-06": null, "2021-09": null, "2021-12": null, "2022-03": 0, "2022-06": 0.0473, "2022-09": 0.0878, "2022-12": 0.114, "2023-03": 0.11, "2023-06": 0.11, "2023-09": 0.11, "2023-12": 0.1, "2024-03": 10.34, "2024-06": 0.1, "2024-09": 0.12, "2024-12": 0.03, "2025-03": 0.1294, "2025-06": 0.09, "2025-09": 0.1228, "2025-12": null, "2026-03": 0,
EPS CAGR: 0.00%
EPS Trend: 3.4%
Last SUE: -0.22
Qual. Beats: 0
Revenue Revenue of HLN over the last years for every Quarter: 2021-03: 2306, 2021-06: 2306, 2021-09: 2490, 2021-12: 2490, 2022-03: 2627, 2022-06: 2627, 2022-09: 2892, 2022-12: 2892, 2023-03: 2986, 2023-06: 5738, 2023-09: 2798, 2023-12: 5564, 2024-03: 2919, 2024-06: 5694, 2024-09: 2780, 2024-12: 5539, 2025-03: 2740, 2025-06: 5480, 2025-09: null, 2025-12: 5515.783497, 2026-03: null,
Rev. CAGR: 23.63%
Rev. Trend: 58.4%
Last SUE: -0.14
Qual. Beats: 0
Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: HLN Haleon

Haleon plc develops, manufactures, and sells consumer healthcare products globally. Its portfolio includes oral health, vitamin/mineral/supplement (VMS), and over-the-counter (OTC) medicines.

The company operates across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. This broad geographic reach is common for established consumer health companies seeking diversified revenue streams.

Key brands include Sensodyne (oral health), Centrum (VMS), Theraflu (respiratory), Voltaren (pain relief), and Tums (digestive health). The consumer healthcare sector often relies on strong brand recognition to drive sales.

Haleon was founded in 1715 and changed its name from DRVW 2022 plc in February 2022. For further detailed analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • Consumer health product demand drives revenue growth
  • Raw material costs impact profit margins
  • Regulatory approvals crucial for new product launches
  • Global economic slowdown reduces discretionary spending
Piotroski VR‑10 (Strict) 7.5
Net Income: 2.78b TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.48 > 1.0
NWC/Revenue: -1.98% < 20% (prev -31.14%; Δ 29.16% < -1%)
CFO/TA 0.17 > 3% & CFO 5.43b > Net Income 2.78b
Net Debt (7.27b) to EBITDA (4.76b): 1.53 < 3
Current Ratio: 0.92 > 1.5 & < 3
Outstanding Shares: last quarter (4.48b) vs 12m ago -1.77% < -2%
Gross Margin: 63.76% > 18% (prev 0.61%; Δ 6.31k% > 0.5%)
Asset Turnover: 57.63% > 50% (prev 49.42%; Δ 8.22% > 0%)
Interest Coverage Ratio: 7.61 > 6 (EBITDA TTM 4.76b / Interest Expense TTM 557.5m)
Altman Z'' 5.37
A: -0.01 (Total Current Assets 4.54b - Total Current Liabilities 4.92b) / Total Assets 32.57b
B: 0.85 (Retained Earnings 27.80b / Total Assets 32.57b)
C: 0.13 (EBIT TTM 4.24b / Avg Total Assets 33.44b)
D: 1.73 (Book Value of Equity 27.89b / Total Liabilities 16.12b)
Altman-Z'' Score: 5.37 = AAA
Beneish M -3.14
DSRI: 0.98 (Receivables 2.12b/1.90b, Revenue 19.27b/16.96b)
GMI: 0.96 (GM 63.76% / 61.43%)
AQI: 0.86 (AQ_t 0.80 / AQ_t-1 0.93)
SGI: 1.14 (Revenue 19.27b / 16.96b)
TATA: -0.08 (NI 2.78b - CFO 5.43b) / TA 32.57b)
Beneish M-Score: -3.14 (Cap -4..+1) = AA
What is the price of HLN shares? As of April 07, 2026, the stock is trading at USD 9.93 with a total of 4,749,966 shares traded.
Over the past week, the price has changed by -0.80%, over one month by -3.50%, over three months by -3.41% and over the past year by +8.98%.
Is HLN a buy, sell or hold? Haleon has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HLN.
  • StrongBuy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the HLN price?
Analysts Target Price 12.1 21.8%
Haleon (HLN) - Fundamental Data Overview as of 02 April 2026
Market Cap GBP = 33.74b (44.64b USD * 0.7559 USD.GBP)
P/E Trailing = 20.4286
P/E Forward = 19.1205
P/S = 4.0471
P/B = 2.0471
P/EG = 2.6578
Revenue TTM = 19.27b GBP
EBIT TTM = 4.24b GBP
EBITDA TTM = 4.76b GBP
Long Term Debt = 7.66b GBP (from longTermDebt, last quarter)
Short Term Debt = 834.5m GBP (from shortTermDebt, last quarter)
Debt = 8.59b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.27b GBP (from netDebt column, last quarter)
Enterprise Value = 41.02b GBP (33.74b + Debt 8.59b - CCE 1.32b)
Interest Coverage Ratio = 7.61 (Ebit TTM 4.24b / Interest Expense TTM 557.5m)
EV/FCF = 14.88x (Enterprise Value 41.02b / FCF TTM 2.76b)
FCF Yield = 6.72% (FCF TTM 2.76b / Enterprise Value 41.02b)
FCF Margin = 14.30% (FCF TTM 2.76b / Revenue TTM 19.27b)
Net Margin = 14.43% (Net Income TTM 2.78b / Revenue TTM 19.27b)
Gross Margin = 63.76% ((Revenue TTM 19.27b - Cost of Revenue TTM 6.99b) / Revenue TTM)
Gross Margin QoQ = 65.03% (prev 64.51%)
Tobins Q-Ratio = 1.26 (Enterprise Value 41.02b / Total Assets 32.57b)
Interest Expense / Debt = 1.90% (Interest Expense 163.0m / Debt 8.59b)
Taxrate = 19.50% (208.7m / 1.07b)
NOPAT = 3.42b (EBIT 4.24b * (1 - 19.50%))
Current Ratio = 0.92 (Total Current Assets 4.54b / Total Current Liabilities 4.92b)
Debt / Equity = 0.52 (Debt 8.59b / totalStockholderEquity, last quarter 16.40b)
Debt / EBITDA = 1.53 (Net Debt 7.27b / EBITDA 4.76b)
Debt / FCF = 2.64 (Net Debt 7.27b / FCF TTM 2.76b)
Total Stockholder Equity = 16.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 2.78b / Total Assets 32.57b)
RoE = 17.26% (Net Income TTM 2.78b / Total Stockholder Equity 16.11b)
RoCE = 17.85% (EBIT 4.24b / Capital Employed (Equity 16.11b + L.T.Debt 7.66b))
RoIC = 13.61% (NOPAT 3.42b / Invested Capital 25.09b)
WACC = 4.69% (E(33.74b)/V(42.34b) * Re(5.49%) + D(8.59b)/V(42.34b) * Rd(1.90%) * (1-Tc(0.19)))
Discount Rate = 5.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.56%
[DCF] Terminal Value 88.44% ; FCFF base≈2.47b ; Y1≈3.05b ; Y5≈5.21b
[DCF] Fair Price = 32.24 (EV 151.05b - Net Debt 7.27b = Equity 143.78b / Shares 4.46b; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 3.35 | EPS CAGR: 0.0% | SUE: -0.22 | # QB: 0
Revenue Correlation: 58.42 | Revenue CAGR: 23.63% | SUE: -0.14 | # QB: 0
EPS current Year (2026-12-31): EPS=0.55 | Chg7d=+0.001 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.8% | Growth Revenue=+3.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg7d=+0.001 | Chg30d=+0.009 | Revisions Net=+1 | Growth EPS=+10.2% | Growth Revenue=+4.4%
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 4.9%)
[Growth] Growth Spread = +1.4% (Analyst 4.4% - Implied 3.0%)
External Resources
Dataroma Stockcircle